Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 07:05 ET | Travere Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe ...
Logo.png
IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight
October 03, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight As potential therapies with novel mechanisms are being...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
September 26, 2023 16:30 ET | Travere Therapeutics, Inc.
Travere Therapeutics to present abstracts at the 17th International Symposium on IgA Nephropathy.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023 07:30 ET | Travere Therapeutics, Inc.
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year)...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 08, 2023 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023 04:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
FILSPARI (sparsentan)
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023 16:04 ET | Travere Therapeutics, Inc.
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial...
Logo.png
IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight
December 14, 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight DelveInsight’s IgA...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022 16:01 ET | Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
October 24, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...